Finance

Beta
Lists
PTX:ASX
Prescient Therapeutics Ltd
A$0.073
+1.39%
(+0.0010) 1D
Jun 5, 4:10:03 PM GMT+10  ·   AUD
All symbols
SymbolPriceChange% Change
Generating top insights for PTX...
Open
A$0.07
High
A$0.07
Low
A$0.07
Mkt. cap
78.95M
Avg. vol.
1.07M
Volume
393.57K
52-wk high
A$0.12
52-wk low
A$0.04
EPS
-A$0.01
Shares outstanding
1.05B
No. of employees
3
Open
A$0.07
High
A$0.07
Low
A$0.07
Mkt. cap
78.95M
Avg. vol.
1.07M
Volume
393.57K
52-wk high
A$0.12
52-wk low
A$0.04
EPS
-A$0.01
Shares outstanding
1.05B
No. of employees
3
News stories
From sources across the web
Profile
Prescient Therapeutics Ltd is a clinical stage oncology company. The company is focused on the development of a universal CAR-T platform, enhanced CAR-T cell manufacturing & function and on two small molecule drug targeted therapies. Wikipedia
About Prescient Therapeutics Ltd
CEOSteven Yatomi-Clarke
Employees3
FoundedMay 22, 1986
Headquarters-
SectorBiotechnology
Websiteptxtherapeutics.com
Previous reportsAll values in AUD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in AUD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
1.55M
1.55M
578.89K
578.89K
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
2.51M
2.51M
1.24M
1.24M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.35M
1.35M
1.13M
1.13M
Operating expense
4.02M
4.02M
2.57M
2.57M
Total operating expenses
4.02M
4.02M
2.57M
2.57M
Operating income
-2.46M
-2.46M
-1.99M
-1.99M
Other non operating income
-
-
-
-
EBT including unusual items
-2.44M
-2.44M
-1.99M
-1.99M
EBT excluding unusual items
-2.44M
-2.44M
-1.99M
-1.99M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-2.44M
-2.44M
-1.99M
-1.99M
Net profit margin
-156.80%
-156.80%
-344.35%
-344.35%
Earnings per share
-
-
-
-
Interest and investment income
20.29K
20.29K
1.86K
1.86K
Interest expense
-
-
-2.97K
-2.97K
Net interest expenses
20.29K
20.29K
-1.12K
-1.12K
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.46M
-2.46M
-
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer